Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg

Andrew J. Roebuck, Quentin Greba, Anna Maria Smolyakova, Mariam Alaverdashvili, Wendie N. Marks, Sumanta Garai, Samantha L. Baglot, Gavin Petrie, Stuart M. Cain, Terrance P. Snutch, Ganesh A. Thakur, Matthew N. Hill, John G. Howland, Robert B. Laprairie

Producción científica: Contribución a una revistaArtículorevisión exhaustiva

24 Citas (Scopus)

Resumen

Childhood Absence Epilepsy (CAE) accounts for approximately 10% of all pediatric epilepsies. Current treatments for CAE are ineffective in approximately 1/3 of patients and can be associated with severe side effects such as hepatotoxicity. Certain cannabinoids, such as cannabidiol (CBD), have shown promise in the treatment of pediatric epilepsies. However, CBD remains limited or prohibited in many jurisdictions, and has not been shown to have efficacy in CAE. Modulation of the type 1 cannabinoid receptor (CB1R) may provide more desirable pharmacological treatments. Genetic Absence Epilepsy Rats from Strasbourg (GAERS) model many aspects of CAE, including cortical spike and wave discharges (SWDs). We have recently demonstrated that Δ9-tetrahydrocannabinol (THC) increases SWDs in GAERS whereas CBD decreases these events. Here, we characterized aspects of the endocannabinoid system in brain areas relevant to seizures in GAERS and tested whether positive allosteric modulators (PAMs) of CB1R reduced SWDs. Both female and male GAERS had reduced (>50%) expression of CB1R and elevated levels of the endocannabinoid 2-AG in cortex compared to non-epileptic controls (NEC). We then administered the CB1R PAMs GAT211 and GAT229 to GAERS implanted with cortical electrodes. Systemic administration of GAT211 to male GAERS reduced SWDs by 40%. Systemic GAT229 administration reduced SWDs in female and male GAERS. Intracerebral infusion of GAT229 into the cortex of male GAERS reduced SWDs by >60% in a CB1R-dependent manner that was blocked by SR141716A. Together, these experiments identify altered endocannabinoid tone in GAERS and suggest that CB1R PAMs should be explored for treatment of absence seizures.

Idioma originalEnglish
Número de artículo108553
PublicaciónNeuropharmacology
Volumen190
DOI
EstadoPublished - jun. 1 2021

Nota bibliográfica

Funding Information:
This work was supported by a Saskatchewan Health Research Foundation (SHRF) Establishment Grant and a CIHR Partnership Grant with GlaxoSmithKline to RBL, and a CIHR Project Grant to JGH. This work was also supported by grant from National Institutes of Health (NIH) to GAT ( EY024717 ). Additional grant funding was provided by CIHR to TPS (# 10677 ) and MNH and a CURE Epilepsy Award to SMC . AJR received scholarship support from NSERC and University of Saskatchewan College of Medicine. AMS received scholarship support from University of Saskatchewan College of Pharmacy and Nutrition, Canada . WNM received scholarship support from SHRF and University of Saskatchewan College of Medicine.

Publisher Copyright:
© 2021 Elsevier Ltd

ASJC Scopus Subject Areas

  • Pharmacology
  • Cellular and Molecular Neuroscience

PubMed: MeSH publication types

  • Journal Article
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

Huella

Profundice en los temas de investigación de 'Positive allosteric modulation of type 1 cannabinoid receptors reduces spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg'. En conjunto forman una huella única.

Citar esto